N&N Scientific, Inc. (N&N) is a pharmaceutical company whose first new product candidate is N-MethanoCarbaThymidine (N-MCT), a promising antiviral drug that has shown potent and selective activity against the Herpes and Orthopox virus families. N&N proposes to develop N-MCT as a therapeutic against the Herpesviridae, Papillomaviridae and Poxviridae genera of Class I dsDNA viruses, including HSV-1, HSV-2, HSV-8, VZV, EBV, smallpox, Vaccinia, cowpox, and HPV.
